HB Wealth Management LLC Cuts Stake in DexCom, Inc. $DXCM

Key Points

• HB Wealth Management cut its stake in DexCom by 79.4% in Q4, selling 19,136 shares and leaving it with 4,958 shares worth about $329,000.
• Q1 results beat expectations—EPS $0.56 vs. $0.47 and revenue $1.19B (up ~15% YoY)—but management reaffirmed full‑year revenue guidance near $5.21B, prompting an after‑hours share dip on limited upside.
• Institutional ownership is very high at 97.75% (Vanguard holds ~49.46M shares), and analysts collectively rate DexCom a "Moderate Buy" with an average target of about $86.50.

HB Wealth Management LLC reduced its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 79.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,958 shares of the medical device company's stock after selling 19,136 shares during the quarter. HB Wealth Management LLC's holdings in DexCom were worth $329,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in DXCM. Holocene Advisors LP bought a new stake in shares of DexCom in the third quarter valued at about $163,964,000. CIBC Private Wealth Group LLC raised its holdings in shares of DexCom by 374.3% in the third quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company's stock valued at $195,666,000 after acquiring an additional 2,294,709 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of DexCom by 2.3% in the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company's stock valued at $3,327,897,000 after acquiring an additional 1,133,638 shares in the last quarter. DSM Capital Partners LLC raised its holdings in shares of DexCom by 76.5% in the third quarter. DSM Capital Partners LLC now owns 2,533,539 shares of the medical device company's stock valued at $170,482,000 after acquiring an additional 1,098,243 shares in the last quarter. Finally, Iron Triangle Partners LP bought a new stake in shares of DexCom in the third quarter valued at about $57,196,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 3.5%

Shares of NASDAQ:DXCM opened at $59.55 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The business's fifty day simple moving average is $65.87 and its 200-day simple moving average is $66.40. The company has a market capitalization of $22.98 billion, a PE ratio of 28.36, a P/E/G ratio of 1.12 and a beta of 1.55. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business posted $0.32 EPS. The business's revenue was up 15.0% compared to the same quarter last year. As a group, equities research analysts predict that DexCom, Inc. will post 2.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent research reports. Sanford C. Bernstein restated an "outperform" rating and issued a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. BTIG Research restated a "buy" rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Morgan Stanley reiterated an "overweight" rating on shares of DexCom in a report on Monday, January 12th. Robert W. Baird set a $87.00 price target on DexCom in a report on Friday, February 13th. Finally, Weiss Ratings upgraded DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, DexCom presently has an average rating of "Moderate Buy" and an average target price of $86.50.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the transaction, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.32% of the company's stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.56 vs. $0.47 consensus and revenue $1.19B vs. ~$1.17B consensus; revenue grew ~15% year‑over‑year, supporting the beat. Read More.
• Positive Sentiment: Underlying profitability and returns remain strong (reported net margin ~17.9% and ROE ~32%), reinforcing the business quality of its continuous glucose monitor (CGM) franchise. Read More.
• Neutral Sentiment: Management reaffirmed full‑year revenue guidance at roughly $5.2–5.3B (company cited a FY revenue target near $5.21B), a range that is roughly in line with consensus but left little upside. Read More.
• Neutral Sentiment: Company posted its press release, slide deck and conference‑call materials for investors to review — useful for digging into regional demand, reimbursement trends, and product cadence. Read More.
• Negative Sentiment: Market reaction was negative after hours: several outlets report shares dropped on concerns that the revenue guidance and lack of clearer upside for FY26 were disappointing relative to the beat. That suggests investors were looking for stronger forward acceleration or additional margin/cost leverage. Read More.
• Negative Sentiment: Coverage notes the stock “dipped after hours” despite beats — a reminder that beats alone may not drive gains unless guidance or cadence implies future upside above consensus. Read More.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.